Hypophosphatemia After Intravenous Ferric Carboxymaltose in Heart Transplant Patients

被引：0
|
作者：
Santulario-Verdu, L. [1 ]
Echeverry-Navarrete, E. [2 ]
Diez-Lopez, C. [2 ]
Canedo-Castelo, M. [1 ]
Juvany-Roig, R. [1 ]
Garcia-Romero, E. [2 ]
Roca-Elias, J. [2 ]
Manito-Lorite, N. [2 ]
Gonzalez-Costello, J. [2 ]
机构：
[1] Bellvitge Univ Hosp, Pharm, Barcelona, Spain
[2] Bellvitge Univ Hosp, Cardiol, Barcelona, Spain
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2022年 / 41卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
512
引用
收藏
页码：S220 / S221
页数：2
相关论文
共 50 条
  • [31] Persistent Hypophosphatemia after Ferric Carboxymaltose Is Associated with Persistent Changes in Biomarkers of Bone Metabolism
    Wolf, Myles
    Schaefer, Benedikt
    Zoller, Heinz
    BLOOD, 2020, 136
  • [32] Intravenous Iron Replacement Therapy With Ferric Carboxymaltose is Safe and Effective in Pediatric Patients With Heart Failure
    Spinner, Joseph A.
    Puri, Kriti
    Powers, Jacquelyn
    Dasari, Tejasvi
    Tunuguntla, Hari
    Choudhry, Swati
    Cabrera, Antonio G.
    Shah, Mona
    Dreyer, William J.
    Denfield, Susan W.
    Price, Jack F.
    CIRCULATION, 2019, 140
  • [33] Severe hypophosphatemia secondary tochronic treatment with endovenous ferric carboxymaltose
    Gonzalez Hidalgo, Virginia
    Moran Lopez, Jesus Manuel
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2022, 69 (08): : 646 - 647
  • [34] Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia
    Bregman, David B.
    Goodnough, Lawrence T.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (02) : 48 - 60
  • [35] Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia
    Seker, Aysun
    Durmus, Nurdan Senturk
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2025, 37 (01):
  • [36] Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review
    Magagnoli, Joseph
    Knopf, Kevin
    Hrushesky, William J.
    Carson, Kenneth R.
    Bennett, Charles L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025,
  • [37] Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside
    Detlie, Trond Espen
    Lindstrom, Jonas Christoffer
    Jahnsen, Marte Eide
    Finnes, Elisabeth
    Zoller, Heinz
    Moum, Bjorn
    Jahnsen, Jorgen
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (04) : 397 - 406
  • [38] Incidence of Fractures after Intravenous Iron: A Retrospective Analysis Comparing Ferric Carboxymaltose and Ferric Derisomaltose
    Zoller, Heinz
    Pammer, Lorenz Michael
    Schaefer, Benedikt
    Saretto, Martina
    Wagner, Sonja
    Pertler, Elke
    Tilg, Herbert
    BLOOD, 2023, 142
  • [39] Hypophosphatemia after injectable iron treatments in adults: Comparison between ferric carboxymaltose and iron sucrose
    Grino, Michel
    Rigaux, Marine
    Lagarde, Anne-Violette
    Robert, Vincent
    Papailhau, Charlotte
    Vincentelli, Marie-Benedicte
    ANNALES PHARMACEUTIQUES FRANCAISES, 2023, 81 (05): : 790 - 800
  • [40] Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia
    Bailie, George R.
    Mason, Nancy A.
    Valaoras, Thomas G.
    HEMODIALYSIS INTERNATIONAL, 2010, 14 (01) : 47 - 54
12345